Trial Profile
Prospective Study With Biological Assessment: Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism; Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms ECAN
- 04 May 2017 New trial record